fem1c Antibody

What is FEM1C and what are its known biological functions?

FEM1C is a human ortholog of the C. elegans FEM-1 gene, involved in protein modification and ubiquitination pathways. It functions as a probable component of E3 ubiquitin-protein ligase complexes where it acts as a substrate recognition subunit . Research indicates that FEM1C plays a significant role in tumor suppression, as its downregulation is associated with enhanced metastasis and proliferation in colorectal cancer (CRC) . The protein recognizes Arg/C-degrons of specific lengths, with seven-residue degrons being sufficient for high-affinity binding . Understanding these functions is critical when designing experiments using FEM1C antibodies.

What is the molecular weight of FEM1C protein and how does this affect antibody selection?

The calculated molecular weight of FEM1C is 68.7-69 kDa . When selecting antibodies for Western blot applications, this molecular weight is crucial for correctly identifying the target protein band. Experimental validation has confirmed that the observed molecular weight matches the calculated weight . When selecting FEM1C antibodies, researchers should ensure that validation data demonstrates recognition of the correctly sized protein to avoid false positive results. This is especially important when studying potential post-translational modifications that might alter the protein's apparent molecular weight.

How can FEM1C antibodies be utilized to investigate epithelial-mesenchymal transition in cancer cells?

FEM1C knockdown studies have revealed significant morphological changes in colorectal cancer cells, transforming them from epithelial to fibroblast-like morphology with dispersed distribution patterns . To investigate this EMT phenomenon, researchers can effectively employ FEM1C antibodies in immunofluorescent assays (IFA) following protocols that involve:

• Cell fixation with 4% paraformaldehyde (20 minutes)

• Permeabilization with 0.2% Triton X-100 (10 minutes)

• Blocking with normal goat serum

• Primary FEM1C antibody incubation (2 hours, recommended dilution 1:500-1:2000)

• Secondary antibody incubation with fluorophore conjugation (1 hour)

• Nuclear counterstaining with Hoechst 33342

This approach allows visualization of FEM1C localization during EMT, which can be correlated with other EMT markers to establish mechanistic relationships between FEM1C downregulation and metastatic potential in cancer cells.

What experimental approaches can be used to correlate FEM1C expression with patient survival data?

To establish clinically relevant correlations between FEM1C expression and patient outcomes, researchers should consider a multi-faceted approach:

Published research demonstrates that patients with colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) who exhibit high FEM1C expression have significantly longer survival rates . When designing such studies, researchers should include appropriate controls and ensure sufficient statistical power through adequate sample sizes.

How does FEM1C's role in the ubiquitin-proteasome pathway influence experimental design?

As a substrate recognition subunit of E3 ubiquitin ligase complexes, FEM1C's functional analysis requires specialized experimental approaches. When designing experiments:

• Consider using proteasome inhibitors (e.g., MG132) alongside FEM1C antibody detection to capture the full spectrum of protein levels

• Implement ubiquitination assays with FEM1C antibody immunoprecipitation to identify potential substrates

• Design degron binding experiments based on the knowledge that FEM1C recognizes Arg/C-degrons of specific lengths (seven-residue degrons show high-affinity binding)

This understanding should influence experimental design when studying protein stability, degradation kinetics, and protein-protein interactions within the ubiquitin-proteasome system context.

What are the optimal conditions for Western blot detection of FEM1C protein?

For reliable Western blot detection of FEM1C, researchers should follow these optimized parameters:

Prior to experimentation, it's advisable to validate the antibody using positive control samples such as HepG2 cells, which have been confirmed to express detectable levels of FEM1C protein . The antibody's specificity should be verified through knockdown experiments to ensure signal reduction corresponds to actual FEM1C depletion.

What controls should be included when performing immunofluorescence with FEM1C antibodies?

For rigorous immunofluorescence experiments with FEM1C antibodies, include the following controls:

• Positive tissue/cell controls: Known FEM1C-expressing tissues (kidney, cardiac tissue, skeletal muscle, or testis)

• Negative controls:

  • Primary antibody omission

  • Non-immune host IgG substitution

  • FEM1C-knockdown cells (siRNA or shRNA treated)

• Subcellular localization controls: Co-staining with organelle markers

• Antibody specificity validation: Peptide competition assays using the immunogen peptide

When interpreting results, researchers should be aware that FEM1C displays different expression levels across tissues, with highest expression in kidney, cardiac tissue, skeletal muscle, and testis, and lower levels in other tissues including cartilage .

What are the technical considerations for flow cytometry applications with FEM1C antibodies?

For intracellular flow cytometry detection of FEM1C, researchers should consider the following technical parameters:

It's essential to optimize permeabilization conditions as excessive treatment may damage epitopes while insufficient permeabilization may prevent antibody access to intracellular targets. Additionally, researchers should validate antibody specificity in their specific cell system through knockdown controls.

How can researchers address weak or absent signal in Western blots for FEM1C detection?

When encountering weak or absent FEM1C signals in Western blots, consider the following troubleshooting steps:

• Verify FEM1C expression in your sample:

  • FEM1C is highly expressed in kidney, cardiac tissue, skeletal muscle, and testis

  • Expression is lower in other tissues including cartilage

  • Consider using HepG2 cells as a positive control

• Optimize protein extraction:

  • Use RIPA buffer with protease inhibitors

  • For membrane-associated fractions, consider specialized extraction methods

  • Avoid repeated freeze-thaw cycles of samples

• Adjust antibody conditions:

  • Try concentrated antibody dilutions (1:500)

  • Extend primary antibody incubation (overnight at 4°C)

  • Test different blocking agents (BSA vs. milk)

• Enhance detection sensitivity:

  • Use higher protein loading (50-80 μg)

  • Employ high-sensitivity ECL substrates

  • Consider using signal enhancers

Remember that FEM1C is downregulated in certain cancer tissues compared to normal tissues , which may naturally result in weaker signals when analyzing tumor samples.

What strategies can address non-specific binding with FEM1C antibodies?

Non-specific binding is a common challenge with antibodies. For FEM1C antibodies, implement these specialized strategies:

• Antibody selection considerations:

  • Use affinity-purified antibodies (protein A purification followed by peptide affinity purification)

  • Consider recombinant antibodies for higher specificity

• Experimental optimizations:

  • Increase blocking stringency (5% BSA with 0.1% Tween-20)

  • Employ gradient salt washes (150-300 mM NaCl)

  • Add 1% non-immune serum from the secondary antibody host species

  • Perform peptide competition assays with the immunogen (C-terminal region peptide, amino acids 455-481)

• Technical modifications:

  • Pre-absorb antibodies against tissues/cells lacking FEM1C expression

  • Filter antibody solutions (0.22 μm) before use

  • Test multiple secondary antibodies to identify those with minimal cross-reactivity

When interpreting results, be aware that the calculated molecular weight of FEM1C is 68.7-69 kDa , which should guide the identification of specific bands.

How can researchers verify the specificity of their FEM1C antibody results?

To ensure experimental results accurately reflect FEM1C biology, implement these verification approaches:

• Genetic validation:

  • siRNA or shRNA knockdown of FEM1C (verify using methods established in published research)

  • Overexpression of tagged FEM1C

  • CRISPR/Cas9 knockout controls

• Peptide competition assays:

  • Pre-incubate antibody with immunogen peptide (C-terminal region between amino acids 455-481)

  • Include gradient concentrations of competing peptide

  • Compare signal reduction between specific and non-specific peptides

• Multiple antibody validation:

  • Use antibodies targeting different FEM1C epitopes

  • Compare staining patterns across different antibody sources

  • Correlate protein detection with mRNA expression data

• Functional validation:

  • Connect antibody-detected expression levels with known FEM1C phenotypes

  • Verify that detected expression changes correlate with expected biological outcomes (e.g., changes in cell morphology from epithelial to fibroblast-like)

How should researchers interpret changes in FEM1C expression in cancer progression studies?

When analyzing FEM1C expression patterns in cancer progression:

• Context-specific interpretation:

  • FEM1C is significantly downregulated in adenomas and CRC tissues compared to normal tissues

  • Downregulation correlates with poorer prognosis in colorectal cancer patients

• Quantitative assessment frameworks:

  • Establish normalized expression ratios (tumor vs. normal)

  • Correlate expression levels with clinical parameters using multivariate analysis

  • Apply statistical thresholds that account for tissue heterogeneity

• Biological significance evaluation:

  • Low FEM1C expression associates with enhanced metastatic potential

  • Changes in expression correlate with epithelial-to-mesenchymal transition signatures

  • Alterations may indicate disruption of ubiquitin-proteasome pathway regulation

Researchers should be mindful that FEM1C appears to function as a tumor suppressor, and its downregulation may represent an important factor in colorectal cancer development .

What insights can FEM1C antibody studies provide about epithelial-mesenchymal transition mechanisms?

FEM1C antibody studies have revealed important mechanistic connections to EMT processes:

• Morphological correlations:

  • FEM1C knockdown transforms cells from epithelial to fibroblast-like morphology

  • Tight cell monolayers convert to dispersed distributions

• Molecular pathway analysis:

  • Proteomic analysis reveals that FEM1C removal affects proteins involved in:

    • Cell adhesion

    • Hypoxia response

    • Myogenesis

    • Epithelial-mesenchymal transition

• Clinical-molecular integration:

  • GSEA analysis demonstrates enrichment of EMT signatures in FEM1C knockdown groups

  • This molecular signature aligns with observed increased metastatic potential

Researchers using FEM1C antibodies should design experiments that can correlate protein expression with these established EMT markers to build comprehensive mechanistic models of how FEM1C regulates cancer cell phenotypes.

How can researchers correlate FEM1C antibody data with patient survival outcomes in clinical studies?

For meaningful clinical correlations with FEM1C expression:

These approaches ensure that antibody-based expression data yields clinically meaningful insights with potential diagnostic or prognostic utility.